Wikisage, the free encyclopedia of the second generation, is digital heritage
Levetiracetam: Difference between revisions
(→Links) |
m (→Links) |
||
| Line 36: | Line 36: | ||
deWolfe & Szafarski | deWolfe & Szafarski | ||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750522/pdf/fneur-04-00121.pdf Levetiracetam use in the critical care setting] | [http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3750522/pdf/fneur-04-00121.pdf Levetiracetam use in the critical care setting] | ||
==[[West syndrome]]== | |||
Mangano S et al. | |||
[http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3672008/pdf/1471-2377-13-48.pdf West syndrome followed by juvenile myoclonic epilepsy: a coincidental occurrence?] | |||
{{Wikidata|Q417227}} | {{Wikidata|Q417227}} | ||
Revision as of 00:57, 30 March 2016
(S)-2-(2-Oxopyrrolidin-1-yl)butanamide is an anticonvulsant medication used to treat epilepsy. It is the S-enantiomer of etiracetam, structurally similar to the prototypical nootropic drug piracetam.
Levetiracetam inhibits high-voltage-activated calcium channels and reduces calcium release from intraneural stores[1]
Extended release
Links
In myoclonic astatic epilepsy should be used with caution in children[2]
ATC
Trinka E., et al 2015 Pharmacotherapy for Status Epilepticus Drugs 75:1499
Safraski J.-P.2015
Vrielynck P. Current and emerging treatments for absence seizures in young patients
Jackson J.-L. et al.2015
Caviness J. N. Treatment of myoclonus
deWolfe & Szafarski Levetiracetam use in the critical care setting
West syndrome
Mangano S et al. West syndrome followed by juvenile myoclonic epilepsy: a coincidental occurrence?
- ↑ newer antiepileptic drugs
- ↑ Paradoxical exacerbation of myoclonic-astatic seizures by levetiracetam in myoclonic astatic epilepsy. BMC paediatrics 15 6
- ↑ http://www.whocc.no/atc_ddd_index/?code=N03AX14&showdescription=yes